H.C. Wainwright Remains a Buy on Cardiol Therapeutics (CRDL)
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on Cardiol Therapeutics (CRDL) with a $9.00 price target. The current analyst consensus is a Moderate Buy with an average target of $8.50. Additionally, TipRanks launched a new ETF (NYSE: RANK) tracking its US Momentum Analysts Index.
H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on Cardiol Therapeutics today and set a price target of $9.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Folkes covers the Healthcare sector, focusing on stocks such as Heron Therapeutics, Zevra Therapeutics, and Traws Pharma. According to TipRanks, Folkes has an average return of -0.8% and a 39.34% success rate on recommended stocks.
Currently, the analyst consensus on Cardiol Therapeutics is a Moderate Buy with an average price target of $8.50.